Breaking News

Cytovance Manufactures ARMO’s Lead Candidate

June 23, 2014

Provides drug product for Phase I trials

Cytovance Biologics has completed GMP manufacture of ARMO BioSciences’ lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-IL-10) being studied in advanced solid tumors.
 
“Cytovance is proud to have been an integral partner in the manufacture of AM0010 bulk drug substance and drug product,” said Darren Head, president and chief executive officer of Cytovance Biologics. “Our team responded to the urgency to get this important drug to patients with advanced solid tumors.”
 
“Cytovance’s responsive and professional team enabled us to accelerate the time to clinic of AM0010 which is currently in a Phase I dose escalation study in patients with cancer,” said Peter Van Vlasselaer, Ph.D., president and chief executive officer of ARMO. “We look forward to continuing our relationship with Cytovance as the manufacturer of product in support of the clinical development of AM0010.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision